|
Balding hair follicle dermal papilla cells contain
higher levels of androgen receptors than those from non-
balding scalp.
Hibberts NA, Howell AE, Randall VA
Department of Biomedical Sciences, University of Bradford,
UK.
J Endocrinol (England) Jan 1998, 156 (1) p59-65
Androgens can gradually transform large scalp hair
follicles to smaller vellus ones, causing balding. The
mechanisms involved are unclear, although androgens are
believed to act on the epithelial hair follicle via the
mesenchyme-derived dermal papilla. This study investigates
whether the levels and type of androgen receptors in primary
lines of cultured dermal papilla cells derived from balding
scalp hair follicles differ from those of follicles from
non-balding scalp. Androgen receptor content was measured by
saturation analysis using the non-metabolisable androgen,
[3H]mibolerone (0.05-10 nM) in a 9-10 point assay. Pubic
dermal fibroblasts and Shionogi cells were examined as
positive controls. Repetitive assays of Shionogi cells showed
good precision in the levels of androgen receptor content
(coefficient of variation = 3.7%). Specific, high affinity,
low capacity androgen receptors were detected in dermal
papilla cells from both balding and non-balding follicles.
Balding cells contained significantly (P < 0.01) greater
levels of androgen receptors (Bmax = 0.06 +/- 0.01 fmol/10(4)
cells (mean +/- S.E.M.)) than those from non-balding scalp
(0.04 +/- 0.001). Competition studies with a range of steroids
showed no differences in receptor binding specificity in the
two cell types. The higher levels of androgen receptors in
cells from balding scalp hair follicles with similar
properties to those from non-balding scalp concur with the
expectations from their in vivo responses to androgens. This
supports the hypothesis that androgens act via the dermal
papilla and suggests that cultured dermal papilla cells may
offer a model system for studying androgen action in
androgenetic alopecia.
United States Patent
Peter H. Proctor
4126 Southwest Freeway, Suite 1616,
Houston, Tex. 77027
|
|
| United States Patent |
[19][11] |
| Patent Number: |
5,352,442 |
| Proctor |
[45] |
| Date of Patent: |
Oct. 4,1994 |
[54] TOPICAL TEMPO
[76] Inventor: Peter H. Proctor,
4126 Southwest Freeway,
Suite 1616, Houston, Tex. 77027
|
|
| [21] Appl. No.: |
21,970 |
| [22] Filed: |
Feb. 24, 1993 |
U.S. PATENT DOCUMENTS
|
|
| 2,409,754 |
10/1946 |
Henze |
260/309.5 |
| 2,986,573 |
5/1961 |
Topliss |
167/65 |
| 3,257,390 |
6/1966 |
Patchett |
260/239.55 |
| 3,461,461 |
8/1969 |
Anthony et al |
260/256.4 |
| 3,527,864 |
9/1970 |
MacMillen et al |
424/177 |
| 3,551,554 |
12/1970 |
Herschler |
424/7.1 |
| 3,896,238 |
7/1975 |
Smith |
424/358 |
| 4,139,619 |
2/1979 |
Chidsey, III |
424/45 |
| 4,189,039 |
1/1980 |
Soldati |
544/12 |
| 4,254,145 |
3/1981 |
Birnbaum |
424/305 |
| 4,327,245 |
8/1982 |
Shapiro |
424/241 |
| 4,344,941 |
8/1982 |
Wiechert |
424/243 |
| 4,367,227 |
1/1983 |
Bingham |
424/243 |
| 4,444,762 |
4/1984 |
Rajadhyaksha |
424/180 |
| 4,456,600 |
6/1984 |
Wiechert |
424/238 |
| 4,488,901 |
12/1984 |
Farkas et al |
71/121 |
| 4,596,812 |
6/1986 |
Chidsey, III |
514/256 |
| 4,866,067 |
9/l989 |
DiSchiena |
514/275 |
FOREIGN PATENT DOCUMENTS
|
|
| 0415598 |
of 0000 |
European Pat. Off. . |
| 0027655 |
4/1981 |
European Pat Off. . |
| 0273202 |
7/1988 |
European Pat. Off. . |
| 0327263 |
8/1989 |
European Pat. Off. . |
| 2198132 |
6/1988 |
United Kingdom . |
| 8302558 |
8/1983 |
World Int. Prop. O. . |
| 8600616 |
1/1986 |
World Int. Prop. O. . |
| 8700427 |
1/1987 |
World Int. Prop. O. . |
OTHER PUBLICATIONS
Anderson, Chemical Abstracts, vol. 90, p. 311K
(1979).
Ando et al., Chemical Abstracts 93:79872n (1980).
Bazzano et al., Journal of American Academy of
Dermatology,
vol. 15, pp. 880-883 (1986).
Barry, Pharmacology of the Skin,
vol. 1, pp. 121-137 (1987).
Cheng et al., Archives of Dermatological Research,
vol. 278, pp. 470-473 (1986).
Cumming. et al., Journal of American Medical
Association,
vol. 247, pp. 1295-1298 (1982).
Dawber, Dermatologica,
vol. 175 suppl. 2, pp. 23-28 (1987).
DeVillez, Archives of Dermatology,
vol 121, pp. 197-202, (1985)
Dostert a d., Xenobiotica,
vol. 15, No. 10, pp. 799-803 (1985).
Ehman et d., Investigative Radiology,
vol. 21, pp. 125-131 (1986).
Feelisch et al., Evr. Journal of Pharmacology,
vol. 139, pp. 19-30 (1987).
Feelisch et al., Evr. Journal of Pharmacology,
vol. 142, pp. 405-409 (1987).
Fox et al., Annals of the New York Academy of
Sciences,
vol. 411, pp. 14-19 (1983).
Primary Examiner-Jose G. Dees
Assistant Examiner-Porfirio Nazario-Gonzalez
Attorney, Agent or Firm-Daniel N. Lundeen; Andrew S.
Pryzant
[57] ABSTRACT
Topical 2,2,6,6-tetramethyl-1-piperdinyloxyl (TEMPO) is
disclosed. The compound has utility in a topical
pharmaceutical formulation for the cosmetic treatment of hair
loss and the cosmetic stimulation of hair growth.
10 claims, No Drawings
United States Patent [19]
Proctor US005472687A [11] Patent Number: 5,472,687
[45] Date of Patent: Dec. 5,1995
[54] TOPICAL PYRIDINE N-OXIDES
[76] Inventor: Peter H. Proctor, Twelve Oaks
Medical Towers 4126 SW. Freeway,
Suite 1616, Houston, Tex. 77027
[21] Appl. No.: 193 ,228 [22] Filed: Feb. 7, 1994
Bourayne et al., Journal de chirnie physique,
vol. 79, No. 2, pp. 139-147 (1982).
Anderson, Chemical Abstracts,
vol. 90, pp. 311K (1979).
Ando et al., Chemical Abstracts,
93:79872n (1980).
Bazzano et al., Journal of American Academy of
Dermatology
vol. 15, pp. 880-883 (1986).
Berry, Pharmacology of the Skin,
vol. 1, pp. 121-137 (1987).
Cheng et al., Archives of Dermatological Research,
vol. 278, pp. 470-473 (1986).
Cumming et al., Journal of American Medical
Association,
vol. 247, pp. 1295-1298 (1982).
Current Therapy,
pp. 599-603 (1984).
Dahl, Men's Fitness,
pp. 93-95 (Feb. 1989).
Dawber, Dermatalogical
vol. 175, suppl. 2, pp. 23-28 (1987).
DeVillez, Archives of Dermatology
vol. 121,pp. 197-202, 1985. Dermatologica,
vol. 175 suppl. 2, pp. 1-56 (Oct. 87).
Dostert et al., Xenobiotica,
vol. 15, No. 10, pp. 799-803 (1985).
Ehman et al., Investigative Radiology,
vol. 21, pp. 125-131 (1986).
Feelisch et al., Evr. Journal of Pharmacology,
vol 139, pp. 19-30 (1987).
Feelisch et al., Evr Journal of Pharmacology,
vol. 142, pp. 405-409 (1987).
Fiedler, Dermatologica,
vol. 175, suppl. 2, pp. 29-35 (1987).
Fox et al., Annals of the New York Academy of
Sciences,
vol. 411, pp. 14-19 (1983).
Goffman et al., International Journal of Radiation,
Oncology, Biology and Physics,
vol. 22, pp. 803-806 (Nov. 4, 1992).
Headington, Current Therapeutic Research,
vol. 36, pp. 1098-1105 (1984).
Hearse et al., Circulation Research,
vol. 60, pp. 375-383 (1987).
Heschler, Chemical Abstracts,
vol. 78, pp. 115-239 (1973). Ignarro et al., Biochemica ct.
Biophysica Acta,
vol. 631, pp. 221-231 (1980).
J., Soc. Cosmetology Chem., (Italy)
vol. 33, pp. 95-96 (Mar./Apr. 1982).
Journal of American Medical Association,
vol. 260, No. 20 (1988).
Karlsson et al., Journal of Cyclic Nucleotide and Protein
Res.,
vol. 10, No. 4, pp. 309-315 (1985).
Kvedar, Journal of American Academic Dermatology,
vol. 12, pp. 215-225 (1985).
Longevity,
vol. 2, No. 3, p. 26 (Jan. 1988).
Lucky, Archives of Dermatology,
vol. 121, pp.57-62 (1985). Messina, Current Therapeutic
Research
vol. 34, pp. 319-324 (1983).
Messina, Current Therapeutic Research,
vol. 38, pp. 269-282 (1985).
Mitchell et al., IBC USA Conference,
South Natick, Mass: (Jun. 27, 1991).
Mittal et al., Proc. of National Academy of Science
USA,
vol. 74, No. 10 pp. 4360-4364 (1977).
Primary Examiner-Porfirio Nazario-Gonzales Attorney, Agent,
or Firm-Sroufe, Payne & Lundeen
ABSTRACT
Topical pyridine N-oxides, including 3-carboxypyridine
N-oxide, niacinamide N-oxide, and
a-(4-pyridyl-1-oxide)N-t-butylnitrone, are disclosed. The
topical compositions have utility in a topical pharmaceutical
formulation for the cosmetic treatment of hair loss and the
cosmetic stimulation of hair growth.
10 Claims, No Drawings
OTHER PUBLICATIONS
Myllyla et al., Biochemical and Biophysical Research
Communications,
vol. 89, No. 1, pp. 98-102 (1979).
Dooley et al., Biochemical and Biophysical Research
Communications,
vol. 96, No. 2, pp. 823-830 (1980).
Rao et al., Chemical Abstracts,
vol. 80, No. 12, Abs. No. 64397u, p. 315 (1974).
Jahagirdar et al., Chemical Abstracts,
vol. 82, No. 22, Abs. No. 145912b, p. 398 (1975).
Straehle et al., Chemical Abstracts,
vol. 93, No. 3, Chem Abs. No. 21526m (1980).
Anderson, Chemical Abstracts,
vol. 90, pp. 311K (1979): Ando et al., Chemical Abstracts,
93:79872n (1980).
Bazzano et al., Journal of American Academy of
Dermatology,
vol. 15, pp. 880-883 (1986).
Berry, Pharmacology of the Skin,
vol. 1, pp. 121-137 (1987).
Cheng et al., Archives of Dermatological Research,
vol. 278, pp. 470-473 (1986).
Cumming et al., Journal of American Medical
Association,
voL 247, pp. 1295-1298 (1982).
Current Therapy,
pp. 599-603 (1984).
Dahl, Men's Fitness,
pp. 93-95 (Feb. 1989).
Dawber, Dermatologica,
vol. 175, suppl. 2, pp. 23-28 (1987).
DeVillez, Archives of Dcrmatology,
vol. 121, pp. 197-202, (1985).
Dermatologica,
vol. 175, suppl. 2, pp. 1-56 (Oct. 1987).
Dostert et al., Xenobiotica,
vol. 15, No. 10, pp. 799-803 (1985).
Ehman et al., investigative Radiology,
vol. 21, pp. 125-131 (1986).
Feelisch et al., Evr. Journal of Pharmacology,
vol. 139, pp. 19-30 (1987).
Feelisch et al., Evr. Journal of Pharmacology,
vol. 142, pp. 405-409 (1987).
Fiedler, Dermatologica,
vol. 175, suppl. 2, pp. 29-35 (1987).
Pox et al., Annals of the New York Academy of
Sciences,
vol. 411, pp. 14-19 (1983).
Goffman et al., International Journal of Radiation,
Oncology, Biology and Physics,
vol. 22, pp. 803-806 (Nov. 4, 1992).
Headington, Current Therapeutic Research,
vol. 36, pp. 1098-1105 (1984).
Hearse ct al., Circulation Research,
vol. 60, pp. 375-383 (1987).
Primary Examiner-Porfirio Nazario-Gonzales Attorncy, Agent,
or Firm-Sroufe, Payne & Lundeen
[57] ABSTRACT
SOD for treating hair loss is disclosed. The SOD has
utility in a topical pharmaceutical formulation for the
cosmetic treatment of hair loss and the cosmetic stimulation
of hair growth. The SOD comprises copper salicylate, copper
aspirinate, indomethacin-copper, or a complex of an amino acid
or peptide and a transition metal.
19 Claims, No Drawings
|